Iterum Therapeutics plc (ITRMF) FCF Margin (2017 - 2025)
Iterum Therapeutics (ITRMF) posted quarterly FCF Margin of 1912.56% for Q3 2025, up 95.3% quarter-over-quarter from 40710.81% in Q1 2019.
Iterum Therapeutics plc (ITRMF) FCF Margin (2017 - 2025) Analysis & Trends
Iterum Therapeutics' FCF Margin history runs 4 years deep, the most recent figure standing at 1912.56% for Q3 2025.
- In Q3 2025, FCF Margin changed N/A year-over-year to 1912.56%; the TTM figure through Sep 2025 stood at 5007.18% (changed N/A YoY), while the FY2019 annual figure was 221475.68%, down 21257556.0% from the prior year.
- FCF Margin for Q3 2025 stood at 1912.56%, up from 40710.81% in the prior quarter.
- The five-year high for FCF Margin was 1912.56% in Q3 2025, with the low at 1912.56% in Q3 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1,912.56% |
| Mar 31, 2019 | -40,710.81% |
| Dec 31, 2018 | -10,547.28% |
| Sep 30, 2018 | -10,831.10% |
| Jun 30, 2018 | -7,006.49% |
| Mar 31, 2018 | -6,105.24% |
| Dec 31, 2017 | -2,914.04% |
| Sep 30, 2017 | -3,515.72% |